UroGen Pharma Ltd. (NASDAQ:URGN) Expected to Announce Earnings of -$1.36 Per Share

Brokerages forecast that UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) will report ($1.36) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for UroGen Pharma’s earnings, with the lowest EPS estimate coming in at ($1.58) and the highest estimate coming in at ($1.18). UroGen Pharma reported earnings of ($1.17) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 16.2%. The business is expected to issue its next earnings report before the market opens on Monday, January 1st.

On average, analysts expect that UroGen Pharma will report full year earnings of ($4.90) per share for the current fiscal year, with EPS estimates ranging from ($6.02) to ($4.36). For the next year, analysts expect that the company will post earnings of ($3.58) per share, with EPS estimates ranging from ($3.97) to ($2.91). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for UroGen Pharma.

UroGen Pharma (NASDAQ:URGN – Get Rating) last issued its quarterly earnings data on Monday, March 21st. The company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). UroGen Pharma had a negative net margin of 230.67% and a negative return on equity of 256.66%. The company had revenue of $16.17 million for the quarter, compared to the consensus estimate of $16.15 million.

A number of research analysts recently issued reports on URGN shares. Berenberg Bank started coverage on UroGen Pharma in a report on Wednesday, April 27th. They set a “buy” rating and a $20.00 target price on the stock. The Goldman Sachs Group lifted their target price on UroGen Pharma from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, March 22nd. Zacks Investment Research lowered UroGen Pharma from a “hold” rating to a “sell” rating in a report on Friday. Finally, HC Wainwright lowered their target price on UroGen Pharma from $34.00 to $26.00 in a report on Tuesday, March 22nd.

A number of institutional investors and hedge funds have recently modified their holdings of URGN. Parallel Advisors LLC increased its stake in UroGen Pharma by 6,383.0% in the 1st quarter. Parallel Advisors LLC now owns 3,047 shares of the company’s stock worth $28,000 after purchasing an additional 3,000 shares in the last quarter. Sterling Investment Advisors Ltd. purchased a new position in UroGen Pharma in the 3rd quarter worth about $34,000. Denali Advisors LLC purchased a new position in UroGen Pharma in the 1st quarter worth about $36,000. Citigroup Inc. increased its stake in UroGen Pharma by 63.0% in the 4th quarter. Citigroup Inc. now owns 5,612 shares of the company’s stock worth $53,000 after purchasing an additional 2,169 shares in the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in UroGen Pharma by 359.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 3,559 shares of the company’s stock worth $60,000 after purchasing an additional 2,785 shares in the last quarter.

Shares of NASDAQ URGN opened at $6.21 on Friday. UroGen Pharma has a fifty-two week low of $5.61 and a fifty-two week high of $19.66. The firm’s 50-day simple moving average is $7.86 and its 200 day simple moving average is $9.74.

UroGen Pharma Company Profile (Get Rating)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

See Also